Loading
A phase 1/2 trial of ADC in prostate cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by MBrace Therapeutics, now recruiting.
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT07145255 by MBrace Therapeutics, with 150 participants planned, started 2025-09-03 and due to reach its primary completion in 2029-09-30. Interventions recorded: ADC.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MBrace Therapeutics and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Prostate cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/